No Data
Wanbangde Pharmaceutical's HIE Drug Gets FDA Nod for Clinical Trial
It is expected to fill the gap in the Global neonatal HIE treatment field, as Wanbangde Pharmaceutical Holding Group's subsidiary WP103 clinical trial application has been accepted by the FDA.
① Currently, no Pharmaceutical product containing Huperzine A has been approved for the market in the USA, and there are no approved drugs globally for the treatment of neonatal HIE. ② Multiple preclinical studies have shown that Huperzine A has significant potential for treating neonatal HIE, with the hope of addressing the pathophysiological challenges of hypoxia-ischemia through a comprehensive mechanism of action.
Wanbangde Pharmaceutical Holding Group (002082.SZ): The clinical trial application for its subsidiary WP107 Pharmaceutical has been accepted by the FDA.
On December 15, Glonghui reported that Wanbangde Pharmaceutical Holding Group (002082.SZ) announced that its wholly-owned subsidiary Wanbangde Pharmaceutical Group Co., Ltd. received a written response from the USA Food and Drug Administration (referred to as "FDA") on December 15, 2024. The clinical trial application for WP107 (Huperzine A oral solution), independently developed by the company, for the treatment of "generalized myasthenia gravis" has officially been accepted. WP107 (Huperzine A oral solution) is a new oral formulation for the treatment of generalized myasthenia gravis developed by the company's innovative drug R&D team based on preclinical and clinical data.
Wanbangde (002082.SZ) has completed the establishment of its wholly-owned subsidiary, Zhejiang Wanbangde Industrial and Trade.
Wanbangde Pharmaceutical Holding Group (002082.SZ) announced that the company has decided to invest its own funds to establish a wholly-owned subsidiary, Zhejiang Wanbangde...
Wanbangde Pharmaceutical Holding Group's (SZSE:002082) Earnings Have Declined Over Three Years, Contributing to Shareholders 35% Loss
Wanbangde Pharmaceutical Holding Group (002082.SZ): Currently, the sales of Ginkgo Biloba Leaf Capsules have increased in OTC channels and third-party terminals.
Gelonghui November 22nd │ Wanbangde pharmaceutical holding group (002082.SZ) stated at the investor event that the company's performance fluctuations are mainly affected by the impact of centralized procurement with large quantities of core products, particularly the significant price reduction of the company's core product, Ginkgo leaf capsules, after winning the bid for centralized procurement, with a decrease of approximately 54%, impacting the company's revenue and profit situation. With the gradual expansion and normalization of the centralized procurement policy and the stabilization of medical and pharmaceutical policies, the company is actively adjusting its marketing strategy to digest the pressure brought by centralized procurement. Currently, there is some growth in the Ginkgo leaf capsule OTC channel and the third terminal, as well as in products such as Triamcinolone Acetonide injection and Bromhexine hydrochloride new products.
Wanbangde Pharmaceutical Holding Group Co., Ltd. (SZSE:002082) Not Doing Enough For Some Investors As Its Shares Slump 28%
No Data
